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Abstract 
A recombinant version of the receptor binding domain (RBDv) of human 0~2-macroglobulin (~2M) has been expressed inE. coli and refolded using 
a novel iterative procedure. RBDv (Val~299-Ala ~45t) is extended by 1 5 residues at the N-terminal side of the Lys~3~3-Glu papain cleavage site in human 
~2M. RBDv contains the intra-chain bridge Cyst329-Cys l~  and is soluble and monomeric. Competition experiments with t25I-labelled methylamine- 
treated ~2 M reveal that RBDv binds to the placental receptor for transformed ~2M with a K~ of 8 nM, i.e. the binding affinity of RBDv is of the 
same order of magnitude as the intrinsic affinity for binding of one domain in transformed ~2M to one receptor molecule. 
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1. Introduction 
The a2-macroglobulins (a2Ms) constitute a family of 
large proteinase inhibitors found in the blood of verte- 
brates and invertebrates, and in bird and reptile egg- 
white. Most a2Ms including human a2M are tetrameric 
proteins consisting of approx. 1450 residue subunits. The 
inhibitory function of a2M is achieved primarily through 
entrapment of the protease molecule. This is caused by 
a large-scale structural rearrangement, known as trans- 
formation, initiated by proteolytic leavage within the 
exposed 'bait regions' of a2M. The subunits of a-mac- 
roglobulins from most species contain an intra-chain 
fl-cysteinyl-y-glutamyl thiol ester which becomes highly 
susceptible tonucleophilic attack by e.g. lysyl side chains 
upon transformation. This often leads to covalent immo- 
bilization of the entrapped protease within its molecular 
m 
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cage. For reviews on a2Ms see [1,2]. Transformation of 
a2 M, either achieved by proteolytic leavage of the bait 
region or by cleavage of the thiol esters with primary 
aliphatic amines, elicits the exposure of a receptor-bind- 
ing module, concealed in native a2M [3-5]. 
The receptor for transformed a2 M is termed a2MR/ 
LRP [6-8]. The 515 kDa a-chain of a2MR/LRP is ligand 
binding whereas its 85 kDa fl-chain is membrane span- 
ning [9-11]. a2MR/LRP is found in many tissues, includ- 
ing fibroblasts, adipocytes, macrophages and hepato- 
cytes [3,5,12,13]. 
The receptor-binding domain of a2M appears to reside 
in the C-terminal region of each polypeptide chain [14]. 
This is corroborated by the isolation of a C-terminal 
fragment obtained by limited proteolysis of c~2M-MA, 
RBD (residues 1314-1451), which can compete for trans- 
formed a2M binding sites in azMR/LRP, albeit with an 
affinity of only about 1-2% of that exhibited by trans- 
formed a2M [15-17]. The corresponding domain from 
rat aiM (residues 1313-1451, human azM numbering) 
has recently been expressed in a bacterial system and 
shown to retain biological activity of the same magnitude 
as the proteolytically derived fragments [18]. 
Here we describe the bacterial expression, folding and 
biochemical characterization f a 153-residue polypep- 
tide (RBDv, Val~299-Ala 1451) representing RBD extended 
by 15 residues at the N-terminal side of the Lys13~3-Glu 
0014-5793194l$7.00 © 1994 Federation of European Biochemical Societies. All rights reserved. 
SSDI 00 14-5793(94)00349-Z 
TL Holtet et al. IFEBS Letters 344 (1994) 242-246 243 
c leavage site in human ~2M. We show that in v i tro re- 
fo ld ing o f  this po lypept ide  can efficiently generate a com-  
pact,  correct ly  d isul f ide-br idged molecule  that  is mon-  
omer ic  in so lut ion and exhibits b ind ing to ~2MR/LRP  
with an aff inity approx.  10 t imes h igher  than that  previ-  
ously determined for  the RBD f ragment.  
2. Materials and methods 
2.1. Construction fthe expression plasmid pTTH6ScFX-ct:M-RBDv 
A 462 bp DNA fragment encoding residues Val1299-Ala 14~1 of human 
~2M was amplified, essentially according to [19], over 30 cycles using 
an ABACUS thermocycler (Hybaid Ltd). 1 U Taq DNA Polymerase 
(HT Biotechnology), approx. 50 pg plasmid DNA, containing a full- 
length ~2M cDNA insert (isolated and kindly provided by Dr. T. Kris- 
tensen, Department of Chemistry, University of Arhus) as template, 
and 80 pmole of each of the two primers were used (the underlined 
nucleotides encode a FX~ cleavage site): 
5" CCTGGATCCATCGAGGGTAGGGTCTACCTCCAGACATCCT-3 'and 
5 ' -CCGAAGCTTCAAGCATTTCCAAGATC 3'. 
The amplified DNA fragment was cut with BamHI and HindlII 
(Boehringer), isolated after agarose gel eletrophoresis, and ligated into 
the E. coil expression vector pT7H 6 [20]. After subcloning of the DNA 
fragment the plasmid was modified by insertion in the BamHI site of 
an oligonucleotide (Sc) encoding the amino acid sequence 
GSLPQNPFSTSSTLPRS. The nucleotide sequence of the plasmid in- 
sert was verified using the Sequenase v r. 2.0 DNA sequencing kit (USB 
Corp.). 
2.2. Expression i E. coli of recombinant RBDv protein 
Recombinant RBDv protein was produced by expressing the plasmid 
pTTH6ScFX-c~2MRBDv, which encodes aFXa cleavable fusion protein 
[21], in E. coli DH1 cells as described [22]. At OD600 : 0.8 exponentially 
growing cultures at 37°C were infected with bacteriophage A.CE6 at a 
multiplicity of approx. 5.30 min after infection rifampicin (Sigma) was 
added and the cultures were grown at 37°C for another 3h before cells 
were harvested by centrifugation. Cells were lysed by osmotic shock 
and sonication and total cellular protein extracted into phenol (adjusted 
to pH 8.0 with Tris base). Protein was precipitated from the phenol 
phase by addition of 2.5 vols. of ethanol and isolated by centrifugation. 
The protein pellet was dissolved in 50 mM Tris-HC1, 6 M guanidinium 
chloride, 100 mM dithioerythriol, pH 8.0. Following buffer exchange 
into 50 mM Tris-HC1, 8 M urea, 0.5 M NaC1, 10 mM 2-mercaptoetha- 
nol, 2 mM methionine, pH 8.0, by gel filtration on Sephadex G-25 
(Pharmacia) the crude protein preparation was applied to a 40 ml Ni 2÷ 
activated NTA-Sepharose (Pharmacia) column [23]. The Ni 2+ NTA- 
Sepharose column was then washed with 50 mM Tris-HCl, 6 M guani- 
dinium chloride, 10 mM 2-mercaptoethanol, 2 mM methionine, pH 8.0 
until A 280 of the eluate was stable (approx. 5 column vols.). 
2.3. Refolding and processing of the o~:M-RBDv fusion protein 
The fusion protein was refolded in vitro, while immobilized on the 
Ni 2+ NTA-Sepharose column, using an iterative refolding procedure 
(TLH, ME, and HCT, Patent application o. DK0130/93, DK0139/93; 
manuscript in preparation). After completion of the iterative folding 
procedure the fusion protein was eluted from the Ni z÷ NTA-Sepharose 
column with 50 mM Tris-HC1, 0.5 M NaCI, 10 mM EDTA, pH 8.0. 
Fusion protein that was aggregated and precipitated on the Ni 2+ NTA- 
Sepharose column was eluted with 50 mM Tris-HCl, 8 M urea, 0.5 M 
NaC1, I0 mM 2-mercaptoethanol, 2 mM methionine, pH 8.0. 
Recombinant RBDv was liberated from the N-terminal fusion tail by 
cleavage with 1/50 (w/w) of the restriction protease FX a at room tem- 
perature for 4 h. After cleavage RBDv was isolated from uncleaved 
fusion protein, liberated fusion tail and FX a by gel-filtration on Se- 
phadex G-25 in 50 mM Tris-HC1, I0 mM NaC1, pH 8.0, followed by 
ion-exchange chromatography on Q-Sepharose (Pharmacia). RBDv 
was eluted with a linear gradient over 10 column vols. from 10 mM to 
500 mM NaC1 in 10 mM Tris-HCl, pH 8.0. RBDv eluted at 150 mM 
NaC1. 
2.4. Amino acid and N-terminal sequence analysis 
After hydrolysis for 20 h at l l0°C in vacuo with 6 M HC1, 
0.1% phenol, 5% thioglycollic acid the amino acid composition was 
determined by cation-exchange chromatography [24] modified to per- 
mit determination f half-cystine as cysteine [25]. 
N-Terminal sequence analysis was done by Edman degradation i an 
Applied Biosystems 477A instrument equipped with a 120A on-line 
chromatograph using a polybrene-coated glass filter and Normal-I 
cycles. 
2.5. Binding of c~2M-MA and RBDv to purified human oteMR/LRP 
MaxiSorp microtiter wells (Nunc) were coated with c~zMRILRP by 
incubation for 2 h at room temperature with 100/21 receptor (approx. 
0.5/2g/ml) in 50 mM NaHCO3, pH 9.6. After blocking with 5% bovine 
serum albumin for 2 h, the plates were washed 3 times with 10 mM 
sodium phosphate, 140 mM NaC1, pH 7.4, containing 0.05% Tween-20. 
Incubations with [usI]c~M-MA [10,26] and different concentrations of 
unlabelled ~2M-MA or RBDv were performed for 16 h at 4°C in 100 
/21 10 mM HEPES, 140 mM NaC1, 2 mM CaClz, 1 mM MgC12, 2% 
bovine serum albumin, pH 7.4. Following washing, bound radioactivity 
was released by the addition of 2 x 150/21 10% SDS and determined. 
Non-specific binding of [125I]ct2M-MA to wells not coated with ~2MR/ 
LRP was likewise determined and subtracted from the values deter- 
mined in the binding experiments. Non-specific binding was less than 
0.5% of binding of the added tracer. 
3. Results 
3.1. Rationale for  studying RBDv 
It was found prev ious ly  [16] that  by expos ing RBD 
isolated by proteo lyt ic  d igest ion o f  c~2M-MA to 6 M 
guan id in ium chlor ide fo l lowed by remova l  o f  the dena-  
turant  by dialysis the b ind ing affinity for ~2MR/LRP  
cou ld  not  be fully restored. In  add i t ion  (unpubl ished)  it 
was found  that  RBD freeze-dr ied f rom NH4HCO3 was 
poor ly  soluble in non-denatur ing  buffers at pH 7-8;  the 
mater ia l  that  did go into solut ion was strongly aggre-  
gated, as determined f rom gel f i l tration. 
These results, in con junct ion  with the 1H NMR and 
CD spectra o f  RBD (N.K.  Thomsen,  LS- J  and F .M.  
Poulsen,  unpubl ished) ,  indicated that  RBD might  be a 
marg ina l ly  stable domain .  Indeed,  refo ld ing o f  recombi -  
nant  RBD fai led to produce a monomer ic  p roduct  (not 
shown). 
In the o~2M fami ly  the sequence immediate ly  upst ream 
of  the LysU13-Glu c leavage site is strongly conserved and 
conta ins  a fair number  o f  hydrophob ic  residues [1,2]. 
Therefore ,  this stretch could  conce ivab ly  be an integral  
part  o f  the receptor -b ind ing domain  and might  therefore 
be requi red to establ ish and mainta in  its correct ly  fo lded 
structure. Since ~2M conta ins  a pai red Cys residue at 
pos i t ion 1298 it was decided to invest igate the propert ies  
o f  expressed po lypept ide  start ing at Va11299 (RBDv) .  
3.2. Construction of  the expression plasmid 
p TTH6ScFX-o~2MRBDv 
The 462 bp reading f rame encod ing  the 153 residue 
RBDv was, due to the design o f  the 5" PCR-o l igonuc leo -  
t ide pr imer,  l inked at the 5" end to a nuc leot ide sequence 
encod ing  a c leavage site (GS IEGR)  for FX  a [21]. The 
ampl i f ied DNA f ragment  was subc loned into the E. coli 
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GSLPQNPFSTSSTLPR 
GATCACKCCACAGAAK CTTITAACTKTKGACCCTCCCM 
\/ a$iRBDv 
IfGSHHHHHH S I E G RiY Y GNA*: 
AXGGA’KGCA’KACCAXACCA’KACG GAlCCAl’CGAGGGTAGGG’ICTAC ----- GGAAAT’3.TKAAGCTl.G 
B8Nlt-i Hind III 
Ori 
Fig. 1. Map of the E. coli expression vector pT,H,ScFX-a,MRBDv. After subcloning of the RBDv PCR-fragment into the BamHI and Hind111 
restriction sites of pT,H, [20] the oligonucleotide (SC) was ligated into the BamHI site. The SC nucleotide sequence encodes an amino acid sequence 
capable of accelerating FX, cleavage (unpublished). 
expression vector pT,H, [20]. The N-terminal fusion tail 
of the expression plasmid was further modified in the 
BamHI restriction site by insertion of an oligonucleotide 
encoding the peptide sequence GSLPQNPFSTSSTLPR 
(SC). Insertion of that peptide N-terminal of the FX, 
cleavage site enhances the rate of FX, cleavage required 
to liberate the recombinant protein (unpublished). A 
map of the expression plasmid pT,H,ScFX-ol,MRBDv 
is shown in Fig. 1. 
3.3. Expression, refolding, and processing of the RBD 
fusion protein 
The expression in E. coli, purification, in vitro refold- 
ing, and processing of the RBDv fusion protein was 
analysed by SDS-PAGE as shown in Fig. 2. Approx. 
50% of the fusion protein material was eluted from the 
Ni*+ NTA-Sepharose column with the non-denaturing 
elution buffer (Fig. 2, lane 2). Ninety per cent of the 
soluble fusion protein material appeared monomeric 
yielding an overall efficiency of the folding procedure of 
approx. 45%. The yield of fully processed and purified 
RBDv protein was 0.5 mg/l of culture. 
3.4. Characterization of RBDv 
The amino acid composition of RBDv was determined 
after acid hydrolysis in the presence of thioglycollic acid 
is shown in Table 1. Apart from Asx and Gly a good 
agreement with the composition expected for Va11299- 
Ala’45’ is evident. Further, N-terminal sequence analysis 
(23 residues determined) revealed a perfect match with 
residues Va1’2gg-Gly’32’ (not shown). 
From reducing SDS-PAGE (Fig. 2, lane 5) the size of 
RBDv was estimated at 17 kDa (expected 17.1 kDa). As 
further seen from Fig. 2, lane 4 RBDv was monomeric 
in non-reducing conditions, and its increased mobility 
compared with the reduced state showed that the CYS’~‘~- 
Table 1 
Amino acid composition of RBDv” 
Amino acid Found Expected 
Asx 16.20 15 
Thr 9.51 10 
Ser 15.46 16 
Glx 15.65 15 
Pro 9.24 9 
CYs 2.08 2 
Gly 5.19 4 
Ala 9.31 9 
Val 15.28 16 
Met 2.51 3 
Ile 6.24 I 
Leu 15.00 15 
Tyr 1.69 8 
Phe 6.99 I 
His 3.15 3 
LYS 9.89 10 
Arg 4.01 4 
Trp 0.00 0 
a Molar rations assuming 15 Leu residues, average of four determina- 
tions. 
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Fig. 2. SDS-PAGE analysis (18% gel) of steps in the purification of 
RBDv. Lane 1, crude cell extract; lane 2, eluate from Ni’+ column 
(fusion protein); lane 3, RBDv concentrated by ultrafiltration after 
cleavage with FX,; lanes 4 and 5, RBDv purified by ion exchange 
chromatography; lane 6, size markers (94, 67, 43, 30, 20, and 14 kDa 
from top to bottom). lanes 24 were non-reduced, lanes 1, 5 and 6 were 
reduced. 
cys’444 intra-chain bridge had been formed during re- 
folding. Upon gel filtration on a calibrated column of 
Superdex 75 in non-denaturing conditions RBDv eluted 
as a monomeric protein of approx. 18 kDa. Hence, from 
the criteria employed, RBDv is likely to constitute a 
domain with a well-defined tertiary structure containing 
the bridge Cy~‘~~~-Cys’~. 
3.5. Analysis of receptor binding 
Fig. 3 shows the concentration dependence of inhibi- 
tion of binding of 10 pM [1251]a,M-MA to a,MR/LRP 
by unlabelled a,M-MA and RBDv. Half-maximal bind- 
ing was seen at about 100 pM a,M-MA and at 8 nM 
RBDv. In contrast, for RBD isolated from a,M-MA by 
proteolytic digestion, half-maximal binding occurred at 
approx. 100 nM in a similar experiment [lo] (Fig. 3). The 
inhibition curves for RBDv and RBD were fitted accord- 
ing to a simple one-receptor model with apparent Kd 
values of 8 and 99 nM, respectively, whereas the curve 
for the tetravalent a,M-MA was fitted in accordance 
with its high and low affinity modes [lo]. The high affin- 
ity mode (Kd approx. 40 PM) has been explained by the 
interaction of tetravalent a,M-MA with two or more 
receptors, whereas the low affinity mode (Kd approx. 2 
nM) is thought to represent the intrinsic affinity for bind- 
ing of one domain in a,M-MA to one receptor mole- 
cule. 
4. Discussion 
The presence in a,Ms of a module which becomes 
available for receptor recognition upon transformation 
is an element in a highly sophisticated mechanism for 
scavenging many foreign or spent proteases. The molec- 
ular events resulting in recognition of transformed a,M 
by a,MRILRP and the subsequent endocytosis and deg- 
radation of a,M-protease complexes are not well under- 
stood. 
The receptor binding domain (RBD, G1u1314-Ala1451) 
of a,M has previously been available only in the form of 
a fragment obtained by proteolysis of a,M-MA [ 15-171. 
To permit studies of the recognition of transformed a,M 
by a,MRILRP by amino acid replacement strategies we 
have expressed a variant of RBD (RBDv, Va11299-Ala’451) 
which contains 15 additional residues (Va11299-Lys1313). 
RBDv was produced in E. coli and in vitro refolded using 
a novel iterative refolding procedure. 
By the criteria employed (SDS-PAGE in the absence 
and presence of reductant, gel chromatography, compo- 
sitional and partial sequence analysis) RBDv was judged 
to constitute correctly folded material. 
When assayed for in vitro binding to a,MRILRP 
RBDv was found to specifically displace 1251-a,M-MA, 
corresponding to an apparent Kd of 8 nM. It was deter- 
mined previously, using RBD obtained by proteolysis of 
tetrameric a,M-MA from different species, that Kd was 
approx. 100-300 nM [10,15-171. The only exception was 
RBD from the monomeric rat al-inhibitor-3 (K,, = 10 
nM) [17]. Hence, recombinant RBDv represents a do- 
main which binds to a,MRILRP with an affinity at least 
lo-fold higher than RBD previously isolated from tetra- 
merit a,Ms, and of the same order of magnitude as that 
of a single domain in a,M-MA. 
The expression in E. coli of a recombinant homologue 
of RBD derived from rat a,M was recently described 
U81. 
Based on EI%,z80 m,lcm = 11.5 (which may represent a 
30 
10 
0 
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Free (pmolll) 
Fig. 3. Competition of RBDv (0) and n,M-MA () with 10 pM [‘2SI]a,M- 
MA for binding to purified placental u,MR/LRP immobilised to mi- 
crotiter wells. Binding was measured after incubation for 16 h at 4°C. 
The dashed line shows competition of RBD with [‘251]~,M-MA for 
cc,MRILRP in a similar experiment [lo]. 
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near 2-fold overestimation [ 16,271) Kd was determined to 
be approx. 20 nM for this preparation. 
In the protocol used for expressing RBD from a,M the 
protein was located intracellularly and was soluble [ 181. 
Probably due to the absence of the bridge Cy~‘~*~-Cys’~ 
in CX,M (both residues being replaced by Phe residues) the 
recombinant cqM RBD folded spontaneously. 
The additional 15 residues in the present RBDv con- 
struct appear not only to permit refolding under the 
conditions employed, so that the intra-chain CYS’~~‘- 
Cys’& bridge forms, but they also subtly influence the 
conformation of the folded protein as reflected in an 
increased affinity of RBDv for ol,MR/LRP. 
The present expression and refolding procedure will 
form the basis for introducing specific mutations aimed 
at defining the determinants for receptor recognition. 
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